Functional analysis of human thromboxane synthase polymorphic variants

Pharmacogenetics and Genomics

Volumn 22, Issue 9, 2012, Pages 653-658

  Chen, Chung Ying K ^a   Poole, Elizabeth M ^b,c   Ulrich, Cornelia M ^b,d   Kulmacz, Richard J ^a   Wang, Lee Ho ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b USA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cytochrome p450; enzyme kinetics; genetic polymorphism; thromboxane synthase

Indexed keywords

12 HYDROXYHEPTADECATRIENOIC ACID; HYDROXY FATTY ACID; MALONALDEHYDE; PROSTAGLANDIN H2; PROTEIN VARIANT; RECOMBINANT PROTEIN; THROMBOXANE A2; THROMBOXANE SYNTHASE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ARTICLE; ENZYME ASSAY; ENZYME KINETICS; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYDROXYAPATITE CHROMATOGRAPHY; IN VIVO STUDY; ISOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; TXAS GENE; VASOCONSTRICTION; WILD TYPE;

BACTERIA (MICROORGANISMS);

EID: 84864944615     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283562d82     Document Type: Article

References (38)

1. Dogne JM, Hanson J, de Leval X, Pratico D, Pace-Asciak CR, Drion P, et al. From the design to the clinical application of thromboxane modulators. Curr Pharm Des 2006; 12:903-923.
2. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008; 118:18-35.
3. Yuhki K, Kojima F, Kashiwagi H, Kawabe J, Fujino T, Narumiya S, et al. Roles of prostanoids in the pathogenesis of cardiovascular diseases. Novel insights from knockout mouse studies. Pharmacol Ther 2011; 129: 195-205.
4. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12:1-51.
5. Ullrich V, Nusing R. Thromboxane synthase. From isolation to function. Stroke 1990; 21:IV134-IV138.
6. Haurand M, Ullrich V. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J Biol Chem 1985; 260:15059-15067.
7. Uchida K. Current status of acrolein as a lipid peroxidation product. Trends Cardiovasc Med 1999; 9:109-113.
8. Chaudhary AK, Nokubo M, Reddy GR, Yeola SN, Morrow JD, Blair IA, et al. Detection of endogenous malondialdehyde-deoxyguanosine adducts in human liver. Science 1994; 265:1580-1582.
9. Otteneder MB, Knutson CG, Daniels JS, Hashim M, Crews BC, Remmel RP, et al. In vivo oxidative metabolism of a major peroxidation-derived DNA adduct, M1dG. Proc Natl Acad Sci USA 2006; 103:6665-6669.
10. Chase MB, Baek SJ, Purtell DC, Schwartz S, Shen RF. Mapping of the human thromboxane synthase gene (TBXAS1) to chromosome 7q34-q35 by twocolor fluorescence in situ hybridization. Genomics 1993; 16:771-773.
11. Tazawa R, Green ED, Ohashi K, Wu KK, Wang LH. Characterization of the complete genomic structure of human thromboxane synthase gene and functional analysis of its promoter. Arch Biochem Biophys 1996; 334: 349-356.
12. Yu IS, Lin SR, Huang CC, Tseng HY, Huang PH, Shi GY, et al. TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. Blood 2004; 104:135-142.
13. Scherz PJ, Huisken J, Sahai-Hernandez P, Stainier DY. High-speed imaging of developing heart valves reveals interplay of morphogenesis and function. Development 2008; 135:1179-1187.
14. Genevieve D, Proulle V, Isidor B, Bellais S, Serre V, Djouadi F, et al. Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome). Nat Genet 2008; 40:284-286.
15. Chevalier D, Lo-Guidice JM, Sergent E, Allorge D, Debuysere H, Ferrari N, et al. Identification of genetic variants in the human thromboxane synthase gene (CYP5A1). Mutat Res 2001; 432:61-67.
16. Saito S, Iida A, Sekine A, Kawauchi S, Higuchi S, Ogawa C, et al. Catalog of 680. variations among eight cytochrome p450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet 2003; 48:249-270.
17. Ulrich CM, Carlson CS, Sibert J, Poole EM, Yu JH, Wang LH, et al. Thromboxane synthase (TBXAS1) polymorphisms in African-American and Caucasian populations: evidence for selective pressure. Hum Mutat 2005; 26:394-395.
18. Hsu PY, Tsai AL, Kulmacz RJ, Wang LH. Expression, purification, and spectroscopic characterization of human thromboxane synthase. J Biol Chem 1999; 274:762-769.
19. Yeh HC, Tsai AL, Wang LH. Reaction mechanisms of 15- hydroperoxyeicosatetraenoic acid catalyzed by human prostacyclin and thromboxane synthases. Arch Biochem Biophys 2007; 461:159-168.
20. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002; 30:3894-3900.
21. Wang LH, Tsai AL, Hsu PY. Substrate binding is the rate-limiting step in thromboxane synthase catalysis. J Biol Chem 2001; 276:14737-14743.
22. Wu KK, Le Breton GC, Tai HH, Chen YC. Abnormal platelet response to thromboxane A2. J Clin Invest 1981; 67:1801-1804.
23. Hecker M, Ullrich V. On the mechanism of prostacyclin and thromboxane A2 biosynthesis. J Biol Chem 1989; 264:141-150.
24. Cornish-Bowden A. Fundamentals of enzyme kinetics. 3rd ed. London: Portland Press; 2004.
25. Wang LH, Kulmacz RJ. Thromboxane synthase: structure and function of protein and gene. Prostaglandins Other Lipid Mediat 2002; 68-69:409-422.
26. Ruan KH, Milfeld K, Kulmacz RJ,Wu KK. Comparison of the construction of a 3-D model for human thromboxane synthase using P450cam and BM-3 as templates: implications for the substrate binding pocket. Protein Eng 1994; 7:1345-1351.
27. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29:308-311.
28. Higgs EA, Moncada S, Vane JR. Prostaglandins and thromboxanes from fatty acids. Prog Lipid Res 1986; 25:5-11.
29. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 1978; 47:997-1029.
30. Cathcart MC, Reynolds JV, O'Byrne KJ, Pidgeon GP. The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. Biochim Biophys Acta 2010; 1805:153-166.
31. Moussa O, Riker JM, Klein J, Fraig M, Halushka PV,Watson DK. Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene 2008; 27:55-62.
32. Moussa O, Yordy JS, Abol-Enein H, Sinha D, Bissada NK, Halushka PV, et al. Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. Cancer Res 2005; 65: 11581-11587.
33. Cathcart MC, Gately K, Cummins R, Kay E, O'Byrne KJ, Pidgeon GP. Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Mol Cancer 2011; 10:25.
34. Lemaitre RN, Rice K, Marciante K, Bis JC, Lumley TS,Wiggins KL, et al. Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis 2009; 204:e58-e63.
35. Park SA, Park BL, Park JH, Lee TK, Sung KB, Lee YK, et al. Association of polymorphisms in thromboxane A2 receptor and thromboxane A synthase 1 with cerebral infarction in a Korean population. BMB Rep 2009; 42: 200-205.
36. Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, Dunning AM, et al. Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res 2009; 15:2181-2191.
37. Kimouli M, Gourvas V, Konstantoudaki X, Basta M, Miyakis S, Spandidos DA. The effect of an exon 12 polymorphism of the human thromboxane synthase (CYP5A1) gene in stroke patients. Med Sci Monit 2009; 15:BR30-BR35.
38. Oh SH, Kim YH, Park SM, Cho SH, Park JS, Jang AS, et al. Association analysis of thromboxane a synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. Pharmacogenomics 2011; 12:351-363.